None listed
Conditions
Interventions
Drug : The experimental group received a once-daily intravenous injection of high-dose levofloxacin 750 mg (when clinically improved, same dose of oral tablets), whereas the control group received onc
Sponsors
Ewha Womans University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: radiologic evidence of pneumonia on a chest x-ray and the presence of at least one of the followings: oral temperature greater than 38°C or less than 35.5°C, leukocytosis [white blood cell count (WBC) >10,000/mm3], or a high proportion of banded neutrophils more than 10%. Subjects were enrolled when they exhibited typical clinical signs and symptoms of pneumonia and were able to produce sputum samples.
Exclusion criteria
Exclusion criteria: suspected infection in areas other than the respiratory system; suspected intolerance to the experimental and control drugs; allergy to or severe side-effects from levofloxacin, azithromycin, ceftriaxone, quinolones, macrolides, or beta-lactams; hospital admission more than 2 weeks before the beginning of the study; receipt of intravenous antibiotics in the 24 h before enrollment; creatinine clearance less than 20 mL/min; empyema requiring chest drainage; chronic lung disease with impaired lung function; evidence of aspiration pneumonia; human immunodeficiency virus infection or immunosuppression (CD4+ cell count < 200/cm3); long-term tranquilizer use for treatment of epilepsy; co-morbidity likely to confound clinical evaluation; receipt of any drug for other clinical experiments within 30 days; pregnancy; and breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy: Clinical symptoms and signs, and radiologic findings | — |
Secondary
| Measure | Time frame |
|---|---|
| Microbiologic evaluation;Tolerability and safety | — |
Countries
Korea, Republic of
Contacts
Public ContactJung Chang
Ewha Womans University Medical Center
Outcome results
None listed